Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBIT Margin: 2011-2025

Historic EBIT Margin for Fennec Pharmaceuticals (FENC) over the last 5 years, with Sep 2025 value amounting to -1.52%.

  • Fennec Pharmaceuticals' EBIT Margin rose 7307.00% to -1.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -12.02%, marking a year-over-year decrease of 1543.00%. This contributed to the annual value of 5.40% for FY2024, which is 6550.00% up from last year.
  • Fennec Pharmaceuticals' EBIT Margin amounted to -1.52% in Q3 2025, which was up 94.64% from -28.31% recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' EBIT Margin peaked at 123,075.00% during Q1 2021, and registered a low of -314.25% during Q1 2023.
  • Moreover, its 3-year median value for EBIT Margin was -18.67% (2023), whereas its average is -57.23%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 11,696,121bps in 2022, then surged by 36,841bps in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' EBIT Margin (Quarterly) stood at 7,587.27% in 2021, then slumped by 94,946bps to 1,047.37% in 2022, then slumped by 106,605bps to -18.67% in 2023, then surged by 689bps to -11.79% in 2024, then spiked by 7,307bps to -1.52% in 2025.
  • Its last three reported values are -1.52% in Q3 2025, -28.31% for Q2 2025, and -9.23% during Q1 2025.